I wrote a short editorial on hyponatremia and it’s effect on mortality for eAJKD. I like the comparison of tolvaptan to Epo. Hopefully we will not have to wait two decades for a properly done RCT with patient oriented outcomes. We know the drug raises the sodium, now let’s see if it reduces fractures, falls and mortality.